skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Drospirenone/ethinyl estradiol 3 mg/20 µg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin

Review

(4281) Views  (1189) Full article downloads

Authors: Gloria Bachmann, Sharon Kopacz

Published Date August 2009 Volume 2009:3 Pages 259 - 264
DOI: http://dx.doi.org/10.2147/PPA.S3901

Gloria Bachmann, Sharon Kopacz

Women’s Health Institute, University of Medicine and Dentistry of New Jersey, USA

Abstract: The combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl estradiol 20 µg (3 mg DRSP/20 µg EE-24/4) supplies 24 days of pills with hormones followed by 4 days of hormone-free pills. This regimen is called the 24/4 regimen. The progesterone component of this oral contraceptive pill (OCP), drospirenone (DRSP), is a fourth-generation progestin that has potent progestogenic, antimineralocorticoid, and antiandrogenic activity, which are unique characteristics compared with the other progestogens contained in most of the other OCPs currently marketed. This formulation, in addition to being an effective long-term OCP, has the additional medical benefit of providing a good parallel treatment for premenstrual dysphoric disorder and moderate acne. The effectiveness of 3 mg DRSP/20 µg EE-24/4, its tolerability and safety, and its additional non-contraceptive benefits are discussed.

Keywords: drospirenone, premenstrual dysphoric disorder, acne vulgaris, contraception, antimineralocorticoid activity, antiandrogenic activity








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Distribution and determinants of patient satisfaction in oncology: A review of the literature
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis
Impact of pharmacist interventions on patients' adherence to antidepressants and patient-reported outcomes: a systematic review
Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
Patient perceptions of multiple sclerosis and its treatment